anti human il6r antibody Search Results


rea291 pe macs miltenyi biotec  (Miltenyi Biotec)
90
Miltenyi Biotec rea291 pe macs miltenyi biotec
Rea291 Pe Macs Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+il6r+antibody/CD126+(IL-6R%CE%B1)+Antibody%2C+anti-human%2C+REAfinity/pmc06525268__41598_2019_43622_MOESM1_ESM-31-104-107
Average 90 stars, based on 1 article reviews
rea291 pe macs miltenyi biotec - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
tocilizumab  (MedChemExpress)
95
MedChemExpress tocilizumab
The effects of IL‐6 on LECs. (A and B) Cell viability of human dermal LECs exposed to IL‐6 for 24 and 48 h was measured using the CCK‐8 assay. The changes of mRNA levels of IL‐1β (C), IL‐6 (D), CCL2 (E), and TGF‐β (F) in human dermal LECs after IL‐6 treatment for 24 and 48 h. For tube‐formation assay (G), IL‐6 significantly increased the total length (H) and number of branches (I) of LECs, whereas <t>Tocilizumab</t> blocked such enhancement effect. For cell scratch assay (J), IL‐6 promotes the migration of LECs with significant increase of wound closure percentage after 12 (K) and 24 h (L), whereas Tocilizumab blocked such enhancement. * p < 0.05, ** p < 0.01, and *** p < 0.001, one‐way ANOVA with Bonferroni's post hoc tests among groups. ANOVA, analysis of variance; CBM, cranial bone maneuver; LECs, lymphatic endothelial cells.
Tocilizumab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+il6r+antibody/Tocilizumab/pmc11848205-197-24-32
Average 95 stars, based on 1 article reviews
tocilizumab - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
mouse anti-human il-6r monoclonal antibody  (USCN Life)
90
USCN Life mouse anti-human il-6r monoclonal antibody
The effects of IL‐6 on LECs. (A and B) Cell viability of human dermal LECs exposed to IL‐6 for 24 and 48 h was measured using the CCK‐8 assay. The changes of mRNA levels of IL‐1β (C), IL‐6 (D), CCL2 (E), and TGF‐β (F) in human dermal LECs after IL‐6 treatment for 24 and 48 h. For tube‐formation assay (G), IL‐6 significantly increased the total length (H) and number of branches (I) of LECs, whereas <t>Tocilizumab</t> blocked such enhancement effect. For cell scratch assay (J), IL‐6 promotes the migration of LECs with significant increase of wound closure percentage after 12 (K) and 24 h (L), whereas Tocilizumab blocked such enhancement. * p < 0.05, ** p < 0.01, and *** p < 0.001, one‐way ANOVA with Bonferroni's post hoc tests among groups. ANOVA, analysis of variance; CBM, cranial bone maneuver; LECs, lymphatic endothelial cells.
Mouse Anti Human Il 6r Monoclonal Antibody, supplied by USCN Life, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+il6r+antibody/mouse+anti+human+il+6r+monoclonal+antibody/pm33893003-51-15-21
Average 90 stars, based on 1 article reviews
mouse anti-human il-6r monoclonal antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
r-plex human il-6r kits  (Meso Scale Diagnostics LLC)
90
Meso Scale Diagnostics LLC r-plex human il-6r kits
The effects of IL‐6 on LECs. (A and B) Cell viability of human dermal LECs exposed to IL‐6 for 24 and 48 h was measured using the CCK‐8 assay. The changes of mRNA levels of IL‐1β (C), IL‐6 (D), CCL2 (E), and TGF‐β (F) in human dermal LECs after IL‐6 treatment for 24 and 48 h. For tube‐formation assay (G), IL‐6 significantly increased the total length (H) and number of branches (I) of LECs, whereas <t>Tocilizumab</t> blocked such enhancement effect. For cell scratch assay (J), IL‐6 promotes the migration of LECs with significant increase of wound closure percentage after 12 (K) and 24 h (L), whereas Tocilizumab blocked such enhancement. * p < 0.05, ** p < 0.01, and *** p < 0.001, one‐way ANOVA with Bonferroni's post hoc tests among groups. ANOVA, analysis of variance; CBM, cranial bone maneuver; LECs, lymphatic endothelial cells.
R Plex Human Il 6r Kits, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+il6r+antibody/monoclonal+anti+human+il+6r+antibody+ruthenium+labeled+with+sulfo+tag+nhs+ester/bio_rxiv__2024__05__11__593709-129-8-13
Average 90 stars, based on 1 article reviews
r-plex human il-6r kits - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mouse anti-human il-6r antibody  (Gen-Probe ltd)
90
Gen-Probe ltd mouse anti-human il-6r antibody
The effects of IL‐6 on LECs. (A and B) Cell viability of human dermal LECs exposed to IL‐6 for 24 and 48 h was measured using the CCK‐8 assay. The changes of mRNA levels of IL‐1β (C), IL‐6 (D), CCL2 (E), and TGF‐β (F) in human dermal LECs after IL‐6 treatment for 24 and 48 h. For tube‐formation assay (G), IL‐6 significantly increased the total length (H) and number of branches (I) of LECs, whereas <t>Tocilizumab</t> blocked such enhancement effect. For cell scratch assay (J), IL‐6 promotes the migration of LECs with significant increase of wound closure percentage after 12 (K) and 24 h (L), whereas Tocilizumab blocked such enhancement. * p < 0.05, ** p < 0.01, and *** p < 0.001, one‐way ANOVA with Bonferroni's post hoc tests among groups. ANOVA, analysis of variance; CBM, cranial bone maneuver; LECs, lymphatic endothelial cells.
Mouse Anti Human Il 6r Antibody, supplied by Gen-Probe ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+il6r+antibody/mouse+anti+human+il+6r+antibody/pm24081898-34-14-18
Average 90 stars, based on 1 article reviews
mouse anti-human il-6r antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rcombinant anti-human il6r antibody fab fragment  (Creative BioMart)
N/A
Recombinant Mouse Antibody Fab Fragment molecule has affinity for the Human IL6R, expressed in Chinese Hamster Ovary cells(CHO).Used for immunoassaytechniques such as: Western blot; Immunofluorescence; Functional StudyStore it under sterile conditions at -20°C upon receiving.
   Buy from Supplier
rcombinant anti-human il6r antibody scfv fragment  (Creative BioMart)
N/A
Recombinant Mouse Antibody scFv Fragment recognises an antigen Human IL6R, expressed in E. coli.Used for immunoassaytechniques such as: Western blot; Immunohistochemistry; Functional Study4°C or -20°C, avoid repeated freezing and thawing.http://www.creativebiolabs.net/Rcombinant-Anti-Human-IL6R-Antibody-scFv-Fragment-4478.htm
   Buy from Supplier
anti-human il6r therapeutic antibody (actemra, roactemra)  (Creative BioMart)
N/A
Recombinant monoclonal antibody to Human IL6R. Tocilizumab (INN, or atlizumab is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of RA in children. It
   Buy from Supplier
rcombinant anti-human il6r antibody  (Creative BioMart)
N/A
Recombinant Mouse Antibody has specificity for an antigen Human IL6R, expressed in Chinese Hamster Ovary cells(CHO).Used for immunoassaytechniques such as: Enzyme-linked Immunosorbent Assay; Western blot; Immunoprecipitation; Functional Study≥1 year at -20°C. If the reconstituted antibody
   Buy from Supplier

Image Search Results


The effects of IL‐6 on LECs. (A and B) Cell viability of human dermal LECs exposed to IL‐6 for 24 and 48 h was measured using the CCK‐8 assay. The changes of mRNA levels of IL‐1β (C), IL‐6 (D), CCL2 (E), and TGF‐β (F) in human dermal LECs after IL‐6 treatment for 24 and 48 h. For tube‐formation assay (G), IL‐6 significantly increased the total length (H) and number of branches (I) of LECs, whereas Tocilizumab blocked such enhancement effect. For cell scratch assay (J), IL‐6 promotes the migration of LECs with significant increase of wound closure percentage after 12 (K) and 24 h (L), whereas Tocilizumab blocked such enhancement. * p < 0.05, ** p < 0.01, and *** p < 0.001, one‐way ANOVA with Bonferroni's post hoc tests among groups. ANOVA, analysis of variance; CBM, cranial bone maneuver; LECs, lymphatic endothelial cells.

Journal: Alzheimer's & Dementia

Article Title: Cranial bone maneuver ameliorates Alzheimer's disease pathology via enhancing meningeal lymphatic drainage function

doi: 10.1002/alz.14518

Figure Lengend Snippet: The effects of IL‐6 on LECs. (A and B) Cell viability of human dermal LECs exposed to IL‐6 for 24 and 48 h was measured using the CCK‐8 assay. The changes of mRNA levels of IL‐1β (C), IL‐6 (D), CCL2 (E), and TGF‐β (F) in human dermal LECs after IL‐6 treatment for 24 and 48 h. For tube‐formation assay (G), IL‐6 significantly increased the total length (H) and number of branches (I) of LECs, whereas Tocilizumab blocked such enhancement effect. For cell scratch assay (J), IL‐6 promotes the migration of LECs with significant increase of wound closure percentage after 12 (K) and 24 h (L), whereas Tocilizumab blocked such enhancement. * p < 0.05, ** p < 0.01, and *** p < 0.001, one‐way ANOVA with Bonferroni's post hoc tests among groups. ANOVA, analysis of variance; CBM, cranial bone maneuver; LECs, lymphatic endothelial cells.

Article Snippet: Then 5 × 10 4 cells were added per well with the treatment of recombinant human IL‐6 protein (20 ng/mL, 206‐IL‐025/CF, R&D Systems, Inc.), Tocilizumab (100 ng/mL, Anti‐Human IL‐6R, Humanized Antibody, HY‐P9917, MedChemExpress), or vehicle, and were incubated for 16 h at 37°C with 5% CO 2 .

Techniques: CCK-8 Assay, Tube Formation Assay, Wound Healing Assay, Migration